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This retrospective study aimed at evaluating the prognostic impact of high serum levels of either the HER-2 extracellular domain
(ECD) or the epidermal growth factor receptor (EGFR) ECD measured using two specific ELISAs in 221 patients with non-small-cell
lung cancer (NSCLC) receiving conventional therapy and 41 nonmalignant pulmonary diseases patients. It was not possible to
discriminate between lung cancer and benign lung disease owing to the lack of sensitivity–specificity relationship of HER-2 and EGFR
ECD levels. Neither HER-2 nor EGFR ECD specific levels were associated with a particular prognosis of NSCLC patients receiving
conventional therapy.
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Future development in non-small-cell lung cancer (NSCLC)
therapy needs a better appraisal of prognostic determinants.
Among the four tyrosine kinase receptors belonging to the HER
family (Hirsch et al, 2003), the HER-2 oncogene encodes a protein
with a molecular weight of 185000D (p185) composed of three
distinct portions: a cytoplasmic domain with tyrosine kinase
activity, a transmembrane domain and an extracellular domain
(ECD). The HER-2 ECD is a glycoprotein referred to as p105 that
can be shed from the cell surface into the blood of normal
individuals and can be elevated in different pathologic conditions
(Molina et al, 1997). This ECD can be accurately quantified in
serum with an enzyme-linked immunosorbent assay (ELISA)
(Zabrecky et al, 1991). The HER-2 ECD releasing seems to be a
process occurring in an early stage of pulmonary carcinogenesis
(Brandt-Rauf et al, 1994). In lung adenocarcinoma, a study showed
a relationship between serum HER-2 ECD level and HER-2
immunohistochemical detection in the tumour (Osaki et al,
1995). Another putative marker of NSCLC is the epidermal growth
factor receptor (EGFR; HER-1), a 170kDa membrane-bound
tyrosine kinase receptor found on the surface of epithelial cells
and implicated in cell growth regulation (Hirsch et al, 2003).
Epidermal growth factor receptor is frequently overexpressed in
NSCLC tumour cells, ranking from 65 to 84% (Bunn and Franklin,
2002). Serum EGFR ECD level could be a candidate tumour marker
for diagnosis, EGFR-targeted therapies (Herbst, 2002) and prog-
nosis of NSCLC. The EGFR ECD can be detected in the serum of
healthy individuals and cancer patients, including NSCLC patients
(Partanen et al, 1994). In this study, we examined the prognosis of
a large NSCLC population followed up over a long period of time,
simultaneously assessing serum HER-2 ECD and EGFR ECD
together with classical prognostic determinants.
PATIENTS AND METHODS
A total of 221 unselected and consecutive histologically proven and
previously untreated NSCLC patients referred to the Montpellier –
Nı ˆmes University Hospital between January 1995 and December
1997 were entered into this study. Clinical data were prospectively
recorded, and a blood sample was taken from each patient at
presentation, the serum was separated and stored at  1801C (in
triplicate) until tested. However, this study was retrospective in
essence, as the decision to test HER-2 and EGFR ECD in the
prospectively built sera bank was taken recently.
Histological subclassification was carried out according to the
World Health Organisation (WHO) classification (WHO, 1982).
Performance status was estimated according to the Eastern
Cooperative Oncology Group (ECOG) criteria, and the percentage
of weight loss during the previous 4 months was recorded. Staging
was carried out according to the fourth edition of the UICC
tumour node metastases (TNM) classification (Sobin et al, 1987),
the American Thoracic Society map of regional pulmonary nodes
(Tisi et al, 1982) and the new Mountain stage grouping (Mountain,
1997). The following investigations were carried out: clinical
examination, standard chest roentgenography, computed tomo-
graphic (CT) scan of chest, brain and upper abdomen, fiberoptic
bronchoscopy, liver sonography and bone scanning. Mediastino-
scopy was used to establish nodal status in NSCLC patients with
nonmetastatic disease and evidence of mediastinal lymph node
enlargement on chest CT-scan.
Non-small-cell lung cancer patients with stage I or II, or
resectable IIIa disease underwent surgery aimed at achieving
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and unresectable stage IIIa or stage IIIb–IV disease received
cisplatin-based chemotherapy. Radiotherapy was applied in locally
advanced stage disease using a concomitant schedule. Best
supportive care, including palliative radiotherapy when needed,
was given to patients with advanced stage disease and poor
performance status. Treatment was chosen according to clinical
and routine biological findings and without knowledge of the
serum EGFR and HER-2 levels. Hence, treatment was not
considered as a prognostic variable in this study.
As a control group, the serum markers were measured in 41
consecutive patients with nonmalignant pulmonary diseases
(infectious diseases 7%, chronic obstructive pulmonary diseases
12%, asthma 56% and miscellaneous 25%). The median age for the
control population was 48 years and sex ratio (F/M) was 0.5.
Serum EGFR level was measured using the Oncogene Science
EGFR Microtiter ELISA. This sandwich immunoassay uses
two mouse monoclonal antibodies; the first one is coated to
the solid phase, and the second, labelled using alkaline phospha-
tase, is used as a tracer. Both capture and detector reagents
specifically recognise the EGFR ECD. The capture antibody
recognises a protein domain on the extracellular portion of EGFR
and neither inhibits EGF binding nor crossreacts with HER-2
oncoprotein. Standards are provided in the kit that allow accurate,
quantitative determinations of EGFR in suitable samples. Serum
HER-2 level was measured by the Oncogene Science HER-2
Microtiter ELISA. This test is a sandwich-type enzyme immu-
noassay that utilises two monoclonal antibodies directed to the
HER-2 ECD. The assay quantitates either the full-length molecule
in tumour tissue (p185) or the ECD (p105) in serum, plasma, cell
cultures and fluids. Coefficients of variation of two sera tested in
different assays were 4% for ELISA tests. Epidermal growth factor
receptor and HER-2 Microtiter ELISA kits were kindly provided by
AstraZeneca.
Receiver operating characteristic (ROC) curves were constructed
using both patient and control subject serum marker levels in an
attempt to establish a sensitivity–specificity relationship for both
HER ECDs. Areas under the ROC curves (AUC–ROC) were
calculated (Hanley and McNeil, 1982). Version 1.0 of AccuROC
for Windows 95 software was used (Vida, 1993). The Youden
indices (sensitivity þ specificity  1) for each threshold value were
generated using a Box–Cox transformation of the serum value of
each marker in order to normalise the marker value (Box and Cox,
1964).
Survival data was updated in May 2003. At this time end point,
nine patients were lost to follow-up (4%). Survival was defined as
the time from treatment initiation (concomitant to serum
sampling) to the date of death. Deaths related to the disease,
regardless of the progression site, or related to treatment were
analysed as events. Deaths from other causes were treated as
censored observations. The median follow-up was 7 years and 4
months. Probability of survival was estimated by the Kaplan–
Meier method (Kaplan and Meier, 1958). Single variable survival
analyses were carried out by means of Wilcoxon and log-rank
tests, and multivariate regression was carried out using Cox’s
model (Cox, 1972). Variables reaching at least a P level less than
15% in univariate analysis were tested in the Cox model. For each
variable, the proportional hazards assumption was tested graphi-
cally. A P level of less than 0.05 was considered significant. The
SAS software package was used.
RESULTS
Patient characteristics are summarised in Table 1. Most of the
main characteristics were similar to those expected for an NSCLC
population, particularly the median age of 62 years (range 31–87;
Interquartile Range: [52.3–70.2]).
Table 1 Patients characteristics and univariate analysis
Variable
Number
(%)
Median
survival
(weeks)
P
(log-rank)
Age (year)
p62 38.6 0.92
462 39.7
Gender
Female 16 (7) 66.1 0.48
Male 205 (93) 35.3
ECOG performance status
o2 118 (53.5) 68.0 o 10
 4
X2 102 (46.5) 23.7
Not done 1 (0.5)
Tumour status (T)
1–2 62 (28) 47.4 0.0009
3–4 159 (72) 34.4
Nodal status (N)
0 58 (26) 97.6 o 10
 4
1–3 163 (74) 31.4
Metastatic status (M)
0 116 (52) 50.4 o10
 4
1 105 (48) 26.1
Stage grouping
I–II 22 (10) 351.7 o 10
 4
III–IV 199 (90) 35.1
Histology
SQC 127 (57.5) 46.4 0.15
ADE 56 (25.5) 37.4
LCC 38 (17) 23.7
Weight loss
o5% 146 (66) 43.7 0.18
X5% 66 (30) 26.9
Not done 9 (5)
Serum CYFRA 21-1 level
p3.6 121 (55) 61.4 o 10
 4
43.6 100 (45) 26.6
Serum NSE level
p12.5 196 (88.6) 42.1 0.04
412.5 25 (11.4) 20.9
Blood leucocyte count
p10.10
9l
 1 113 (51.1) 57.3 0.0008
4 10.10
9l
 1 105 (47.5) 28.4
Missing data 3 (1.4)
Serum albumin level
X32g/l 184 (83.2) 39.7 0.09
o32g/l 32 (14.4) 17.7
Missing data 5 (2.2)
Serum sodium level
X132 208 (94) 38.6 0.12
o132 12 (5.5) 27.3
Missing data 1 (0.5)
Serum alkaline phosphatase level
Normal 191 (86.5) 42.1 0.004
Elevated 27 (12.2) 22.3
Missing data 3 (1.3)
Serum lactate dehydrogenase level
Normal 110 (49.7) 39.0 0.53
Elevated 109 (49.3) 36.1
Missing data 2 (1)
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Sensitivity was assessed in the NSCLC population and specificity
in benign lung disease. Neither serum HER-2 nor EGFR ECD
demonstrated any sensitivity–specificity relationship with
both ROC curves underneath the noninformation line. AUC–ROC
(standard deviation, 95% confidence interval) were 0.34 (0.04,
0.26–0.43) and 0.35 (0.05, 0.26–0.44) for HER-2 and EGFR ECD,
respectively. According to the Youden indices, the best
threshold value could be set at 8.2 ngml
 1 for serum HER-2 ECD,
resulting in the maximum indices (0.23) and gave a 0.45 sensitivity
and a 0.78 specificity. The best threshold value could be set
at 52ngml
 1 for serum EGFR ECD, resulting in the maximum
indices (0.16) and gave a 0.44 sensitivity and a 0.72 specificity.
Although these thresholds resulted in a poor specificity–sensitivity
relationship, they were chosen as the cutoff level for subsequent
survival analyses.
Univariate analysis
Univariate analysis (Table 1) showed that patients affected by one of
the following characteristics had a shorter survival in comparison
with the opposite status of each variable: performance status equal
to or worse than 2, tumour status of T3–T4, positive nodal status
(N1–N3), presence of metastases, stage grouping of III or IV, high
serum alkaline phosphatase level, leucocyte count of 10000 or
higher, serum NSE level higher than 12.5ngml
 1 and serum CYFRA
21-1 level higher than 3.6ngml
 1. Neither serum HER-2 (Figure 1)
nor EGFR ECD (Figure 2) were significant determinants of
prognosis. However, the former was marginally significant when
arbitrarily using the 15ngml
 1 threshold as used in breast cancer
populations (five out of 221 patients, log-rank test 0.07).
Multivariate analysis
As the aim of the study was to determine the prognostic value of
HER-2 and EGFR ECD serum levels, these variables were tested in
the Cox model despite the lack of predictive value in univariate
analysis. According to the Cox model, 12 additional variables were
eligible to be tested in the Cox regression hazards model. They
represented less than 10% of the total observed events (192 deaths)
and therefore complied with the current recommendation (Harrell
et al, 1985).
The following variables were independent determinants of a
poor outcome: a poor performance status, hazard ratio (95 %
confidence interval): 2.28 (1.59–3.27), a positive nodal status 2.0
(1.38–2.99), presence of metastases 1.48 (1.04–2.09), a nonsqua-
mous histology 1.38 (1.01–1.90), a high serum CYFRA 21-1 level
1.5 (1.08–2.09), a high serum NSE level 2.28 (1.42–3.66) and an
elevated alkaline phosphatase level 1.6 (1.01–2.54). Finally, the
Cox model has been run again after coding HER-2 as a continuous
variable. This variable did not modify the results of the Cox model.
DISCUSSION
In a study of serum HER-2 ECD level in NSCLC (Ardizzoni et al,
2001), 20% (16 out of 82) of the patients presented with a high
serum level and showed a shorter overall survival when compared
with patients having a serum level o 73fmml
 1 (13.5ngml
 1). A
major difficulty in analysing the HER-2 serum level literature
relates to the inconsistency of threshold level definition. In our
study, the lack of sensitivity–specificity relationship of serum
HER-2 and EGFR ECD levels preclude a clear definition of the
cutoff level to be subsequently used in a clinical setting. Therefore,
it was not possible to discriminate between lung cancer and benign
lung disease. The variables shown in this study, to be independent
determinants of a poor outcome, are well-established survival
features of NSCLC (i.e. poor performance status, positive nodal
status, presence of metastases, nonsquamous histology, an elevated
alkaline phosphatase level, a high serum CYFRA 21-1 level and a
high serum NSE level). Neither HER-2 nor EGFR ECD specific
levels were associated with a particular prognosis in this disease.
Uncertainty regarding the prognostic effect of serum HER ECDs
might depend on the poor reliability of these molecules as tumour
markers.
One could object that, as functional markers, HER-2 and EGFR
might be related to a particular prognosis only for those patients
receiving specific targeted therapy. However, in the setting of
EGFR-targeted therapy, two different studies of EGFR tissue
Serum EGFR ECD
p52ngml
 1 96 (43) 28.4 0.23
452ngml
 1 125 (57) 44.7
Serum HER-2 ECD
p8.2ngml
 1 115 (51) 37.3 0.30
4 8.2ngml
 1 106 (49) 42.1
EGFR¼epidermal growth factor receptor; ECD¼extracellular domain;
NSE¼neuron-specific enolase; ADE¼adenocarcinomas; SQC¼squamous cell
carcinomas; LCC¼large-cell carcinomas.
Table 1 (continued)
Variable
Number
(%)
Median
survival
(weeks)
P
(log-rank)
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Figure 1 Probability of survival of NSCLC patients according to
pretreatment serum HER-2 extracellular domain level.
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Figure 2 Probability of survival of NSCLC patients according to
pretreatment serum EGFR extracellular domain level.
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immunohistochemical staining intensity and clinical efficacy.
Conversely, activity of anti-HER-2 therapy in lung cancer could
be positively influenced by a 2þ or 3þ HER staining. The low
frequency of such high expression in NSCLC weakens the clinical
usefulness of this observation. Whether or not serum HER ECD
levels could help in the management of specific targeted therapy
remains to be evaluated. However, the recent discovery of a EGFR
gene mutation as a predictive factor of response to gefitinib
therapy seems a more reasonable and promising approach (Lynch
et al, 2004).
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